Literature DB >> 21328447

Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma.

Hidenori Shiraha1, Shin-ichi Nishina, Kazuhide Yamamoto.   

Abstract

Runt-related transcription factor 3 (RUNX3) is reported as a tumor suppressor gene for gastric cancer, and may be important in the development of hepatocellular carcinoma (HCC). RUNX3 expression is frequently lost or decreased by hemizygous deletion or hypermethylation of its promoter lesion in HCC. The significance of decreased expression of RUNX3 in HCC has not been fully elucidated, but is likely related to dysfunction of cell cycle regulation, decrement of apoptosis, enhancement of angiogenesis, and development of epithelial-mesenchymal transition. RUNX3 is a promising candidate as a tumor suppressor gene for HCC.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21328447     DOI: 10.1002/jcb.22973

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  17 in total

Review 1.  Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.

Authors:  Faisal Saeed Khan; Ijaz Ali; Ume Kalsoom Afridi; Muhammad Ishtiaq; Rashid Mehmood
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

2.  Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract.

Authors:  Remond J A Fijneman; Rebecca A Anderson; Ethan Richards; Jieming Liu; Marianne Tijssen; Gerrit A Meijer; Janae Anderson; Annette Rod; Michael G O'Sullivan; Patricia M Scott; Robert T Cormier
Journal:  Cancer Sci       Date:  2012-01-19       Impact factor: 6.716

Review 3.  The RUNX family in breast cancer: relationships with estrogen signaling.

Authors:  N-O Chimge; B Frenkel
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

Review 4.  Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma.

Authors:  Yuewu Yang; Zhiqiang Ye; Zengcheng Zou; Gemin Xiao; Gangjian Luo; Hongzhi Yang
Journal:  Tumour Biol       Date:  2014-07-19

5.  Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.

Authors:  Vikash Reebye; Pål Sætrom; Paul J Mintz; Kai-Wen Huang; Piotr Swiderski; Ling Peng; Cheng Liu; Xiaoxuan Liu; Steen Lindkaer-Jensen; Dimitris Zacharoulis; Nikolaos Kostomitsopoulos; Noriyuki Kasahara; Joanna P Nicholls; Long R Jiao; Madhava Pai; Duncan R Spalding; Malkhaz Mizandari; Tinatin Chikovani; Mohamed M Emara; Abdelali Haoudi; Donald A Tomalia; John J Rossi; Nagy A Habib
Journal:  Hepatology       Date:  2013-12-09       Impact factor: 17.425

6.  Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.

Authors:  Lijun Xu; Hongwen Lan; Yushu Su; Jun Li; Jingwen Wan
Journal:  Drug Des Devel Ther       Date:  2015-06-03       Impact factor: 4.162

7.  Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis.

Authors:  Wei-Ping Mu; Jian Wang; Qiong Niu; Ning Shi; Hai-Feng Lian
Journal:  Onco Targets Ther       Date:  2014-07-10       Impact factor: 4.147

8.  Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.

Authors:  Yi Wang; Xiuguang Qin; Jieqing Wu; Bo Qi; Yipeng Tao; Wenju Wang; Fulei Liu; Hanchen Li; Baosheng Zhao
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

9.  Clinicopathological significance and potential drug target of RUNX3 in breast cancer.

Authors:  Ying-Ying Yu; Chao Chen; Fan-fei Kong; Wei Zhang
Journal:  Drug Des Devel Ther       Date:  2014-12-05       Impact factor: 4.162

10.  Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3.

Authors:  Shu Meng; Jiatian Cao; Xiaoping Zhang; Yuqi Fan; Lu Fang; Changqian Wang; Zhongwei Lv; Da Fu; Yigang Li
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.